All In Biotech

Drug Trial Radar · NCT05035082

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

REALYSE - Comparative Effectiveness of Once-daily Oral Semaglutide Versus Any Other Oral Glucose-lowering Medication in a Real-world Adult Population With Type 2 Diabetes on Metformin Monotherapy in US Based Health Care Systems - a Pragmatic Randomized Trial

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,018 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,018

Actual

Start

Sep 1, 2021

Primary completion

Jun 18, 2025

Study completion Jun 18, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. The doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. The study will last for about 1 year. Participants will have 2 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit. In addition, the study personnel will contact participants up to 3 times during this period and to follow-up on information from participant doctors visits. Participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. All clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. The study team will collect information from these visits recorded in the medical chart. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • semaglutideDrug

    Oral administration The doctor will give a prescription for the medicine and tell how to take it.

  • oral glucose-lowering medications (commercially available)Drug

    Oral administration The doctor will give a prescription for the medicine and tell how to take it.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c)Time frame: Week 0, year 1

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Stewart Medical Group

    Alhambra, California

  • FDRC

    Costa Mesa, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Raincross Medical Group

    Riverside, California

  • Reyes Clinical Research, Inc

    Miami, Florida

  • DC Research Works

    Marietta, Georgia

  • Urban Family Practice Assoc

    Marietta, Georgia

  • Macoupin Research Group

    Gillespie, Illinois

  • UnityPoint Health-Diabetes Care Center

    Peoria, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Kernodle Clin Dpt-Pvt Diagnost

    Burlington, North Carolina

  • OnSite Clinical Solutions, LLC_Charlotte

    Charlotte, North Carolina

  • WakeMed Garner Hlthplx

    Garner, North Carolina

  • Clinical Research of Gastonia

    Gastonia, North Carolina

  • Valley Weight Loss Clinic

    Fargo, North Dakota

  • Diab & Endo Assoc of Stark Co

    Canton, Ohio

  • Central Ohio Clinical Research LLC

    Columbus, Ohio

  • Jefferson Endocrinology Assocs

    Philadelphia, Pennsylvania

  • Tristar Clin Investigations, PC

    Philadelphia, Pennsylvania

  • Preferred Primary Care Physicians_Pittsburgh

    Pittsburgh, Pennsylvania

  • AnMed Health IMA

    Anderson, South Carolina

  • Baylor Scott & White Res Inst

    Dallas, Texas

  • Hill Country Medical Associates

    New Braunfels, Texas

  • DCT-Stone Oak

    San Antonio, Texas

  • Chrysalis Clinical Research

    St. George, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.